1.Investment in one of our Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility.2.Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company.3.Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary.4.Funding the working capital requirements of our Company.5.Investment in our Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”) and Ratnatris Pharmaceutical Private Limited (“Ratnatris”) to fund their working capital requirements.6.Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.